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Abstract: Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment
options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate
lung tissue have experienced rapid growth in both preclinical animal models and translational clinical
studies. In this review, the current knowledge of these cell therapies is summarized. Although further
investigations are required, these studies indicate that cell therapies are a promising therapeutic
approach for the treatment of idiopathic pulmonary fibrosis.
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1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and severe disease with no known
cause. Damage to the alveolar epithelium is believed to be an important early pathogenic event in IPF.
Epithelial cell damage and death result in gaps in epithelial basement membranes. The migration of
fibroblasts and myofibroblasts into the alveolar space through these gaps leads to intra-alveolar fibrosis
with an exaggerated accumulation of extracellular matrix (ECM) components. This fibrosis disturbs
the normal lung architecture, leading to lung dysfunction and failure [1–3]. To date, pirfenidone and
nintedanib are the only drugs approved for the treatment of IPF. Although these two drugs have shown
efficacy in reducing the rate of decline in lung function and slowing the pace of disease progression,
they are not able to halt disease progression [4,5]. Currently, it is not clear if pirfenidone or nintedanib
can increase survival or improve symptoms such as dyspnoea and cough [4,5]. In addition, both
compounds have shown significant side effects and neither is curative [4,5]. Due to the few options
available for the treatment of IPF patients, there is a search for new therapeutic approaches. In this
sense, over the last decade, several studies related to cell therapies have been conducted in both animal
models and in patients with IPF in order to find new effective therapies for this devastating disease
(Table 1).
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Table 1. Results of preclinical and clinical studies of cell-based therapies for idiopathic pulmonary fibrosis (IPF).
Study Cell Source Dose and Route ofAdministration
Time of Cell Transplantation
after Injury Study Design Results Ref.
Preclinical BM-MSCs 5 × 106/mouse, IV Immediately or 7 days afterBLM instillation BLM-induced fibrosis in mice
Reduced inflammation and collagen
deposition [6]
Preclinical BM-MSCs 2.5 × 106/rat, IV Immediately or 7 days afterBLM instillation BLM-induced fibrosis in rats
Reduced collagen deposition and
reduced oxidative stress [7]
Preclinical BM-MSCs 5 × 105/mouse, IV Immediately after BLMinstillation BLM-induced fibrosis in mice
MSCs protect lung tissue, blocking the
pro-inflammatory cytokines TNF-α and
IL-1
[8]
Preclinical BM-MSCs 5 × 106/mouse, IV 6 h after BLM instillation
Myelosuppression and
bone-marrow MSC
administration. BLM induction
in mice
Suppression of inflammation and
production of reparative growth factors [9]
Preclinical BM-MSCsHGF knockdown BM-MSCs 5 × 10
4/g body weight, IV
6–8 h after BLM administration
or 9 days later BLM-induced fibrosis in mice
Reduced fibrosis, reduced levels of
interleukin-1b and apoptosis, increased
levels of HGF; these effects were
mediated in part by the HGF
[10]
Preclinical
BM-HSCs MSCs
MSCs: transduced (MSCs-KGF)
MSCs: non-transduced (MSCs-GFP)
HSCs: transduced HSCs with
HSCs-KGF
HSCs: non-transduced (HSCs-GFP)
0.5 × 106/mouse, IV for
MSCs and 0.6 × 106, IV for
BM-HSC transplantation
MSCs: 8 h after BLM
instillation, second dose 3 days
after HSCs: 7 weeks after
BM-HSC transplantation
BLM instillation + doxycycline
BLM-induced fibrosis in mice
and BM-MSC administration.
BM-HSC transplantation and
BLM-induced fibrosis
MSCs and HSCs reduced collagen
disposition. Transduced HSCs
attenuated histological damage through
endogenous ATII cell proliferation
induced by KGF.
[11]
Preclinical Human BM-MSCs 5 × 105/mouse, IV 24 h after BLM instillation BLM-induced fibrosis in mice
Reduction of oxidative stress,
endoplasmic reticulum stress,
and TGF-β1 produced by alveolar cells
[12]
Preclinical Human BM-MSCs 5 × 106/mouse, IV 1, 2, 3, or 4 days after BLMinstillation
BLM-induced fibrosis in
immunodeficient NOD/SCID
and NOD/SCID/β2
microglobulin (β2M) null mice
Low levels of BM-MSCs engraft [13]
Preclinical Hypoxia-preconditioned BM-MSCs 5 × 10
5/mouse,
intratracheal
3 days after BLM instillation BLM-induced fibrosis in mice Reduction of inflammation and fibrosisand improved pulmonary function [14]
Preclinical
Oncostatin M preconditioned BM-MSCs
Oncostatin M preconditioned HGF
knockdown BM-MSCs
2 × 105/mouse,
intratracheal
3 days after BLM instillation BLM-induced fibrosis in mice
Reduction of inflammation and fibrosis
factors and improved pulmonary
function
[15]
Preclinical BM-MSCs 106/rat, IV 4 days after BLM instillation BLM-induced fibrosis in rats
Reduction of inflammation and fibrosis
factors (IL-1β, TGF-β, VEGF, IL-6,
TNF-α, and NOS)
[16]
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Table 1. Cont.
Study Cell Source Dose and Route ofAdministration
Time of Cell Transplantation
after Injury Study Design Results Ref.
Preclinical
BM-MSCs
Amnion-MSCs
Human amniotic epithelial cells (hAECs)
1 × 106/mouse, IV 10 days after BLM (72 h afterthe second BLM dose)
BLM-induced fibrosis in mice
(2 repeated doses at 0 days and
7 days)
Amnion-MSCs, BM-MSCs, and hAECs
exert a wide range of anti-inflammatory
effects. Among all cells, amnion-MSCs
were more effective, reducing fibrosis
and TGF-β, and increasing MMP-9
activity, GM-CSF secretion and
induction of IL-1RA.
[17]
Preclinical BM-MSCs transfected with HGF 3 × 106/rat, intratracheal 7 days after BLM instillation BLM-induced fibrosis in rats Reduced collagen deposition andreduced fibrosis in Ashcroft score [18]
Preclinical Human BM-MSCs overexpressingmicroRNAs let-7d or miR-154 5 × 10
4/mouse, IV 7 days after BLM instillation BLM-induced fibrosis in mice
B-MSCs overexpressing let-7d revealed
shifts in animal weight loss as well as
reduced collagen deposition and
decreased CD45-positive cells
[19]
Preclinical Young-donor adipose-MSCsOld-donor adipose-MSCs 5 × 10
5/mouse, IV 24 h after BLM instillation
BLM-induced fibrosis in
old mice >22 weeks old
Young adipose MSCs showed greater
effect on decreased fibrosis, (MMP)-2
activity, oxidative stress, and markers of
apoptosis
[20]
Preclinical Adipose-MSCs 2.5 × 10
4 or 2.5 ×
105/mouse, IV
7 days after BLM instillation BLM-induced fibrosis in mice
Inhibition of both pulmonary
inflammation and fibrosis in
a dose-dependent manner
[21]
Preclinical Human adipose-MSCs 3 × 105/mouse, IP
Were simultaneously
administered in the latter 2
months of the 4-month BLM
regimen at the same time of
BLM
Biweekly administration of
a total of 8 doses of BLM
during 4 months in mice
Reduced epithelial cell hyperplasia and
reduced inflammatory cell infiltration
and fibrosis. Inhibition of apoptosis in
epithelial cells and in the expression of
TGF-β)
[22]
Preclinical Human placenta-MSCsMurine placenta-MSCs
4 × 106/mouse, IP
1 × 106/mouse, IV or
intratracheal
15 min after intratracheal BLM
instillation BLM-induced fibrosis in mice
Reduction in neutrophil infiltration and
in the severity of BLM-induced lung
fibrosis
[23]
Preclinical Human placenta-MSCs 1 × 105/mouse, IV 3 days after BLM instillation BLM-induced fibrosis inMyD88-deficient mice
Reduced collagen deposition, MyD88
and TGF-β signalling activation,
and production of pro-fibrotic cytokines
[24]
Preclinical Human umbilical-MSCs 1 × 106/mouse, IV 24 h after BLM instillation BLM-induced fibrosis in mice
Inhibition of inflammation and fibrosis
and down-regulation of lung cytokine
and TIMP expression while
up-regulating MMPs
[25]
Preclinical Amnion stem cells (ASCs) 5 × 106/mouse, IV 2 h after BLM instillation, 0 or14 days after BLM instillation BLM-induced fibrosis in mice
Inhibition of collagen deposition,
preservation of pulmonary function,
and decreased CCL2 expression on
either day 0 or day 14
[26]
Preclinical iPSCsiPSC conditioned medium 2 × 10
6/mouse, IV 24 h after BLM instillation. BLM-induced fibrosis in mice
Decreased myeloperoxidase activity and
neutrophil infiltration. Rescue of
pulmonary function. Reduced collagen
deposition
[27]
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Table 1. Cont.
Study Cell Source Dose and Route ofAdministration
Time of Cell Transplantation
after Injury Study Design Results Ref.
Preclinical iPSCs 2 × 105/mouse, IV 24 h after BLM instillation BLM-induced fibrosis in mice
Suppression of inflammatory responses,
the TGF-b1/Smad2/3 pathway,
and EMT
[28]
Preclinical iPSCs derived to ATII cells 5 × 10
5/mouse,
intratracheal
24 h after BLM instillation. BLM-induced fibrosis in mice Reduced lung inflammation andcollagen deposition [29]
Preclinical
Human- ESCs derived to epithelial
lineage-specific cells (ATII, ATI and club
cells)
105 Human-ESC,
intratracheal
7 days after BLM instillation BLM-induced fibrosis in mice
Reduced collagen and increased levels
of ATI and ATII and progenitors in the
lungs
[30]
Preclinical Lung resident-MSCs 0.15 × 10
6 or 0.25 ×
106/mouse, IV
Immediately after BLM
instillation BLM-induced fibrosis in mice
Decreased pulmonary damage and
mitigation of the development of PAH.
Decreased lymphocyte and granulocyte
infiltration
[31]
Preclinical ATII cells 2.5 × 106/rat, intratracheal 3, 7 or 14 days after BLM BLM-induced fibrosis in rats Reduced collagen deposition andreduced severity of pulmonary fibrosis [32]
Preclinical ATII cells 2.5 × 10
6/rat, 14 days after
BLM
14 days after BLM BLM-induced fibrosis in rats Restoration of lung surfactant proteinlevels [33]
Preclinical LSCs formed basically by ATI, ATI andclub cells 5 × 10
6 LSC/rat, IV
At the same moment of
intratracheal BLM instillation BLM-induced fibrosis in rats
LSCs attenuated the progression and
severity of fibrosis, decreased apoptosis,
protected alveolar structures,
and increased angiogenesis
[34]
Clinical Autologous adipose-MSCs 0.5 × 10
6 cells/kg of body
weight, intratracheal
Mild to moderate IPF patients
Phase1b, prospective,
non-randomized, non-placebo
(n = 14)
Adipose-MSCs were safe and no
deterioration of functional parameters
and indicators of quality of life were
observed
[35]
Clinical Heterologous placenta-MSCs 1 × 10
6 or 2 × 10 6 cells/kg
of body weight, IV
Mild to moderate IPF patients
Phase 1b, non-randomized,
non-placebo, dose escalation
study (n = 8)
Placenta-MSCs were safe, with no
evidence of worsening fibrosis [36]
Clinical Heterologous ATII cells 1000 to 1200 × 10
6
cells/patient, intratracheal
Mild to moderate IPF patients
Clinical study,
non-randomized, non-placebo
(n = 16)
ATII cells were safe and well tolerated,
and halted disease progression [37]
Clinical Heterologous BM-MSCs 20, 100, or 200 × 106cells/patient, IV Mild to moderate IPF patients
phase 1b, non-randomized,
non-placebo, dose escalation
study (n = 9)
BM-MSCs were safe, no evidence of
worsening fibrosis [38]
Abbreviations: BM, bone marrow; MSCs, mesenchymal stem cells; HGF, hepatocyte growth factor; HSCs, hematopoietic-stem cells; GFP, green fluorescent protein; KGF, keratinocyte
growth factor; NOD/SCID, nonobese diabetic/severe combined immunodeficiency; AEC, amniotic epithelial cells; RA, receptor antagonist; MYD88, myeloid differentiation primary
response 88; iPSCs, induced pluripotent stem cells; ESCs, embryonic stem cells; ATII cells, alveolar type II cells; ATI, alveolar type I cells; LSCs, lung spheroid cells; IV, intravenously; IP,
intraperitoneally; BLM, bleomycin; TNF-α, tumour necrosis factor-α; IL, interleukin; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor; NOS, nitric oxide;
MMP, metalloproteinases; GM-CSF, granulocyte macrophage colony-stimulating factor; TIMP, tissue inhibitor of metalloproteinases; CCL2, monocyte chemoattractant protein-1; EMT,
epithelial to mesenchymal transition; PAH, pulmonary arterial hypertension.
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The implantation of cells with the ability to proliferate and migrate to injured sites combined
with the capacity to secrete multiple paracrine factors that can regulate endothelial and epithelial
permeability, decrease inflammation, inhibit bacterial growth, and enhance tissue repair, is the main
objective of these cell therapies for the treatment of IPF. To reach this goal, many different cell types
have been assayed, including stem cells and lung progenitor cells. This review focuses on the main
cells therapies used in preclinical and clinical studies.
2. Stem Cells
A stem cell is defined as an undifferentiated cell with three primary functions: self-renewal,
clonality and the potential to differentiate into different types of cells and tissue. To achieve this
remarkable task, they can undergo an intrinsically asymmetric cell division whereby in the first
division one daughter cell is maintained as a self-renewing stem cell and the other becomes a precursor
or progenitor cell that will give rise to differentiated cells (Figure 1A). Alternatively, the stochastic
differentiation process can take place. In this case, the divided stem cell could be differentiated into
two daughter cells, or the stem cell could be divided into two new stem cells (Figure 1B). In accordance
with the ability to differentiate, stem cells can be categorized into five groups: totipotent, pluripotent,
multipotent, oligopotent, and unipotent [39]. The classification of stem cells also depends on their
origin: embryonic stem cells (ESCs), adult stem cells (ASCs), and adult specific cells that have been
"reprogrammed" genetically to adopt a stem cell-like state (Figure 2). This last type of stem cells is
called induced pluripotent stem cells (iPCs) (Figure 2).
Figure 1. Schematic representation of a stem cell division in relation to self-renewal and the
repopulation potential. (A) Asymmetric replication, giving rise to a differentiating cell and a stem cell;
this division maintains the stem cell pool; (B) Stochastic model of division, giving rise to two stem cells
with higher repopulation potential or to two differentiated cells.
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Figure 2. Schematic representation of the main sources for stem cells that have been used for the
development of cellular therapies in pulmonary fibrosis.
2.1. Embryonic Stem Cells
Embryonic stem cells derived from blastocysts are self-renewable and pluripotent cells that
generate a variety of specialized cell types including pulmonary cells (Figure 2) [40]. Advances in lung
regeneration or repair using ESCs have developed more slowly than expected, since obtaining these
cells has historically involved the destruction of embryos with the obvious ethical issues. Moreover, the
protocols for differentiating ESCs into lung cells have not been very accurate, although new protocols
are now available to obtain differentiated lung cells from ESCs [41].
2.2. Adult Stem Cells
2.2.1. Bone Marrow Stem Cells
In the bone marrow (BM), there are two main populations of stem cells: the hematopoietic stem
cells (HSCs) and the mesenchymal stromal stem cells (MSCs) (Figure 2).
• Hematopoietic stem cells
Hematopoietic stem cells are recognized as the main source of adult stem cells with the ability
to self-renew and to differentiate into all blood lineages. Hematopoietic stem cells are multipotent
and they differentiate into several cell types, including endothelial [42] and epithelial cells [43].
Some groups have observed that, in the lung, HSCs are able to become alveolar type II (ATII) cells
after BM transplantation [44–46].
• Mesenchymal stromal stem cells
Mesenchymal stromal stem cells are non-blood adult stem cells that were originally isolated from
BM stroma and described by Friedenstein in 1968 [47]. Thereafter, MSCs can be isolated from other
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tissues, such as adipose tissue, placenta, umbilical cord, amniotic fluid and cord blood (Figure 2).
Mesenchymal stromal stem cells are multipotent cells capable of differentiating into a number of
different cell lines and exerting anti-proliferative, immune-modulatory, anti-inflammatory, anti-fibrotic
and microbicide effects [48]. Mesenchymal stromal stem cells have the ability to home to sites of injury
regardless of the route of administration [49,50]. Due to the combination of multipotency, migratory
ability, and immunoprivileged state (MSCs do not express major histocompatibility factor II, making
allogeneic transplant possible) [51], MSCs have shown promise as a novel therapeutic agent in multiple
diseases. Mesenchymal stromal stem cells have been the most widely studied ASCs for the treatment
of pulmonary diseases. A large number of preclinical studies in pulmonary fibrosis showed that MSCs
migrate to the damaged pulmonary tissue, inhibit inflammation, and could differentiate into lung
epithelial cells and confer a functional benefit (Table 1).
2.2.2. Induced Pluripotent Stem Cells
Induced pluripotent stem cells are adult cells that have been genetically reprogrammed to an ESC
cell-like state (Figure 2). In 2006, Takahashi and Yamanaka reported for the first time the successful
reprogramming of somatic cells to an ESC cell-like pluripotent state [52]. The reprogramming requires
the ectopic expression of four or even fewer factors (Oct 3/4, Sox2, c-Myc, and Klf4) responsible
for maintaining pluripotency [52,53]. To date, a great variety of human and murine terminally
differentiated somatic cells have been reported to be reprogrammed into iPSCs. Simultaneously, iPSCs
can differentiate into any of the cell types responsible for the formation of particular tissues and organs,
including ATII-like cells [54]. The derivation of iPSCs bypasses ethical concerns associated with the
use of human ESCs and also provides an alternative source of cells that can be used as donor cells for
transplantation therapy.
2.2.3. Lung Stem/Progenitor Cells
Lung stem and progenitor cells have attracted significant interest, as they are able to differentiate
into lung epithelial cells contributing to epithelial maintenance and injury repair [55]. The lung
epithelium contains several different types of epithelial cell populations, including ciliated, goblet,
and basal cells in the proximal airways, and ciliated, club (or secretory), neuroendocrine, and basal
cells in the distal airways. The pseudostratified airway epithelial layer continues into a flat epithelial
layer composed of ATI cells and ATII cells in the alveolar regions. Lung stem and progenitor cells are
found throughout the pulmonary epithelium (Figure 2).
Basal cells are morphologically characterized by their small height and by their position attached
to the basement membrane of the stratified and pseudostratified airway epithelium [56]. In recent
years, basal cells have been considered stem/progenitor cells since in vitro and in vivo studies have
demonstrated that these cells were able to self-renew and have multipotent properties, since they could
generate not only more basal cells, but also ciliated, goblet and club cells [57–59]. These observations
have been reaffirmed using in vivo models of injury/repair which have demonstrated that the
disruption of the basal cell layer triggered an uncontrolled proliferation of the underlying stroma,
resulting in an accumulation of fibroblasts and immune cells that subsequently obliterate the
airways [60]. Recently, it has been revealed that there are multiple heterogeneous subpopulations
of basal cells. However, in human lungs these basal cell subpopulations are still not well known.
There are subsets expressing distinct keratin (KRT) isoforms. Smirnova and colleagues have identified
different basal cell subtypes in healthy lungs compared with an IPF human lung, characterized by
various combinations of p63, KRT5, and KRT14 expression [56]. They found several combinations of
KRT5+/− KRT14+/− p63+/− basal cells in the human airways in distinct locations; however, none with
the combination of KRT5+, KRT14+, and p63+ were found in the healthy distal lung. In contrast, this
combination KRT5+, KRT14+, and p63+ was the most frequent in IPF distal lungs, indicating that basal
cell populations in IPF patients are functionally different to basal cells in healthy lungs. Moreover,
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these IPF basal cell populations express differentiated epithelial cell markers, showing that in a context
of injury/disease, they are likely attempting to regenerate the epithelium [56].
Club or secretory cells are the predominant epithelial cell of the bronchioles. The club cell
population at large is molecularly characterized by the expression of secretoglobin family 1A member 1
(Scgb1a1) and are known to self-renew and generate ciliated cells during epithelial homeostasis and in
response to lung damage [61–63]. Recent studies performed in mouse lungs indicate that club cells
are, like basal cells, a highly heterogeneous population. In the large airway, three subsets of club
cells can be discriminated based upon their maturity [57]. Other studies found different club cell
division patterns; one destined to self-renewal and the classical one destined to differentiate specifically
into ciliated cells [61]. In the small airways, two subsets of club cells were first identified based on
their susceptibility to naphthalene-induced injury. One of them is very sensitive to naphthalene
administration and a small subset is able to resist injury [64]. These naphthalene-resistant club cells,
termed ‘variant club cells’, are able to replicate and repopulate the damaged airway epithelium and
they are characterized by low levels of Scgb1a1 expression, in contrast to their conventional club cell
counterparts. Lineage-tracing studies have shown that the population of Scgb1A1+ cells in the small
airways self-renews and can generated ciliated cells in the absence of a basal stem cell compartment.
However, it has been suggested that most ciliated cells in the large airway come from a club cell
differentiation under steady state conditions, mimicking the pattern seen in the small airways [61].
It is interesting to note that, although progenitor cells are often thought of as ‘undifferentiated’ cells,
club cells are functionally differentiated cells that retain progenitor cell activity [61].
In the alveoli, ATII cells that produce pro-surfactant protein C (pro-SPC) and recycle surfactant
proteins are well recognized as progenitors for the alveolar type 1 cells [65]. In the adult, lineage-tracing
analysis has demonstrated that ATII cells maintain the homeostatic turnover of ATI cells and also
contribute extensively to the ATI population following bleomycin (BLM)-induced lung injury [65–67].
Moreover, lineage-tracing analysis has also shown that ATII cells not only generate ATI cells, but can
also self-renew, thus qualifying these cells as stem/progenitor cells of the adult lung alveoli [65].
Treutlein and colleagues have identified a bipotent progenitor cell population in embryos that expresses
both ATII and ATI cell markers [68]. At the moment, it is unclear how to compare an adult ATII cell
with this embryonic one. Along these lines, an ATII cell subset, characterized by Wnt-responsive Axin2
expression, has recently been identified, and these progenitors have a particularly robust capacity
to generate alveolar epithelium [69]. Interestingly, by using cell lineage tracing methods in mice,
it has been shown that club cells can also give rise to ATII and ATI cells during repair processes of
the alveolar epithelium damage [70]. It is likely that further subsets of ATII cells will emerge with
further scrutiny.
Currently, there is a multitude studies that have confirmed the presence of MSCs in the lungs
of mice [64–75] and humans [76–78]. Lung MSCs (lu-MSCs) share some features with BM-MSC
and fulfil the International Society of Cellular Therapy criteria for MSCs, including marker profile
and differentiation capacity [79]. Lung MSCs are localized at the distal tip of the branching airway
epithelium and it has been observed that they can proliferate and differentiate into airway epithelial
stem/progenitor cells in co-culture [80].
3. Preclinical Experiences
Numerous preclinical studies show that cell-based therapies can have beneficial effects in the
treatment of IPF (Table 1). The BLM model is the most used experimental model to study IPF and is
considered a well characterized animal model of IPF since it shares many similarities to human IPF
pathogenesis [81,82]. However, it must be taken into account that the BLM model does not cover all
aspects of the human disease, particularly with regard to the progression of the disease. Therefore,
the translatability of preclinical data to clinical efficacy could be limited. In this review, we have
focused on a selection of studies conducted in the BLM model since other models of pulmonary
fibrosis, such as radiation-induced fibrosis or silica, represent a different disease entity. However,
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comparisons between all published studies are difficult due to the large number of protocols that
have been used. These protocols include different types of stem cells and different routes and times
of cell administration after BLM instillation. Among all of these different variables, the timing for
cell administration is one of the most critical factors determining the therapeutic outcome. In the
BLM model, three developing phases can be distinguished: during the first three days, after the
instillation, an inflammatory phase is triggered; after seven days, fibroblasts begin to proliferate;
and finally, after 15 days, the fibrosis is already established. Ortiz and colleagues were the first to
report that if BM-MSCs were given immediately after BLM instillation, they were engrafted to sites
of lung injury, led to less inflammation and collagen deposition and decreased the expression of
matrix metalloproteinase (MMP)-2 and MMP-9 (Figure 3) [6]. However, these beneficial effects were
not observed if BM-MSCs were given seven days after BLM instillation. Similarly, other studies
showed that only the early administration of BM-MSCs (immediately, 15 min, 6, 8, and 24 h, or 3 and 4
days) after BLM instillation were able to show beneficial effects. In these cases, the BM-MSCs were
engrafted to the injured tissue, decreased the oedema, decreased the expression of pro-inflammatory
and pro-fibrotic cytokines, and decreased the inflammatory cell infiltration, the oxidative stress, the
alveolitis, the collagen deposition, the endoplasmic reticulum stress, the ATII cell apoptosis and the
fibrosis score (Figure 3) [7–16]. However, there exist only few studies investigating the administration
of BM-MSCs seven or more days after BLM instillation. In these cases, most of the beneficial effects
observed when the cells were administered in the early period of BLM instillation are no longer
observed (Figure 3) [6,10,17]. There are two studies where BM-MSCs were modified by the transfection
of hepatocyte growth factor (HGF) [18] or the overexpression of microRNA (let-7 or miR-154) [19]
and were administered after seven days of BLM; these studies showed some positive effects in
reducing collagen deposition and fibrosis (Figure 3). All in all, it is clear that the timing of BM-MSCs
administration is a determining factor of cell therapy biological response. Related to HSCs, there is
only one study that compares HSCs with MSCs as vehicles to deliver keratinocyte growth factor (KGF)
into the BLM lungs [11]. Here, Aguilar and colleagues observed that even though both cell populations
reduced collagen accumulation, only transduced HSCs transplantation greatly attenuated histological
damage. Their conclusion was that the reduced lung damage likely occurs through endogenous ATII
cell proliferation induced by KGF [11]. It is important to take into account that in this case, mice
underwent a HSCs transplant nine weeks before the BLM instillation, so the cells had already been
administered in the animals when fibrosis was induced [11]. However, in this study, it is important to
take into account that the authors focused their work on the therapeutic effect of the KGF and not on
the delivered cells. In this case, the cells are considered a vector to deliver KGF. However, it is difficult
to establish whether the positive effect is due to the cells or to the KGF. In any case, the administration
of modified stem cells for the purpose of inhibiting or overexpressing different cytokines or growth
factors opens a new field of research.
Adipose-mesenchymal stem cells have also been evaluated in some interesting studies [20–22].
Thashiro and colleagues studied the differences between young or old donor adipose-MSCs in old
mice after 24 h of BLM instillation [20]. Their results showed that young adipose-MSCs decreased
pro-inflammatory markers, fibrosis, MMP-2 activity, oxidative stress and markers of apoptosis
(Figure 3). In contrast, old-donor adipose-MSC treatment in old BLM mice did not reduce fibrosis and
related markers. This study clearly demonstrates that there are age-dependent anti-fibrotic properties
of administered cells [20]. Therefore, the age of the donors is an important issue to take into account in
the development of cell therapies for IPF patients, since the results could be different depending on the
age of the cell donors. In another study, Kotany and colleagues demonstrated that after seven days of
BLM instillation, adipose-MSCs inhibited both pulmonary inflammation and fibrosis, which markedly
improved the survival rate of mice in a dose-dependent manner (Figure 3) [21]. In concordance, Lee
and colleagues showed by repeated adipose-MSCs administration at 8, 10, 12, and 14 weeks in a chronic
model of fibrosis (in which BLM was given every 2 weeks for 16 weeks) a reduced hyperplasia of
epithelial cells and reduced inflammation and fibrosis (Figure 3) [22]. These two studies showed that
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adipose-MSCs could have positive effects even when they are administered in the late periods of
BLM instillation.
Figure 3. Mesenchymal stem cells or induced pluripotent stem cells delivered intravenously or
intratracheally home to the sites of injury in the lungs where they exert anti-inflammatory and
anti-fibrotic effects, engage in paracrine signaling and immunomodulation, differentiate into local cell
types, and activate resident stem cells enhancing lung regeneration.
The studies performed with placenta-MSCs also showed encouraging results when the cells were
administered in the early stages of BLM instillation [23,24]. Cargnoni and colleagues investigated
the effect of allogeneic or xenogeneic (murine and human) placenta-MSCs after 15 min of BLM
instillation [23]. Independently of the cell origin, results were similar. A decrease in neutrophil
infiltration and a significant reduction in the severity of fibrosis was observed (Figure 3) [23]. Moreover,
in another study, the administration of placenta-MSCs was effective in decreasing pro-fibrotic markers
of fibrosis [24]. In related studies, the application of stem cells derived from umbilical or amniotic
fluid proved effective, inhibiting the inflammatory response and promoting lung regeneration
(Figure 3) [25,26]. Garcia and colleagues showed that amniotic fluid stem cells have the potential to
cleave monocyte chemoattractant protein-1 (CCL2), which results in the inhibition of parenchymal
remodelling and the development of pulmonary fibrosis even when they have been administered at
the same moment or 14 days after BLM (Figure 3) [26].
Few studies have been conducted using iPSCs with or without differentiating them into ATII-like
cells [27–29]. How and colleagues evaluated two treatments after 24 h of BLM instillation: one with
iPSCs and one with a conditioned medium from iPSCs [27]. Notably, both treatments reduced the
levels of inflammatory cytokines and chemokines, including interleukin (IL)-1, IL-2, IL-10, tumour
necrosis factor α (TNF-α), and collagen deposition (Figure 3). Zhou and colleagues also evaluated
iPSCs administration 24 h after BLM instillation [28]. Their results showed a reduction in inflammatory
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responses, transforming the growth factor β (TGF-β)-1/Smad2/3 pathway and epithelial mesenchymal
transition (EMT) during the progression of BLM-induced pulmonary fibrosis (Figure 3) [28].
Since lung resident stem/progenitor cells are responsible for repairing the damaged alveolar
epithelium in the event of lung damage, a number of studies have been performed using lu-MSC, iPSCs
and ESCs differentiated into ATII cells, or ATII cells directly [29–34]. Zhou and colleagues observed
a beneficial effect of iPSCs differentiated into ATII when the cells were administrated 24 h after BLM
instillation [29]. Their results showed that the ATII cells differentiated from iPSCs were able to reduce
inflammation and fibrosis (Figure 4). Similar results were obtained by Banerjee and colleagues [30].
In this case, they investigated the use of ESCs differentiated into epithelial lineage-specific cells (ATII,
ATI, and Club cells). The cell administration was seven days after BLM instillation and a reduction
in collagen deposition and an increase in the number of ATII, ATI, and lung progenitor cells was
observed (Figure 4) [30]. Another study showed that the administration of lu-MSCs, just after
BLM instillation, also attenuated pulmonary fibrosis, mitigated pulmonary arterial hypertension,
and decreased inflammatory cell infiltration (Figure 3) [31]. Serrano-Mollar and colleagues conducted
two remarkable studies evaluating the therapeutic effect of ATII cells (Figure 4) [32,33]. ATII cells were
administrated at three different times (3, 7, and 15 days after BLM instillation). The results of these
studies showed that ATII cells halt fibroproliferation at all of these time points. However, the most
noteworthy results were the significant reduction of fibrosis and the restoration of surfactant levels 15
days after BLM instillation, during the fibrotic phase [32,33]. A very novel study using lung stem cell
spheroids has been performed by Cores and colleagues [34]. This study was based on the development
of adult lung spheroid cells as an intrinsic source of therapeutic lung stem cells. The administration
of these spheroids just after BLM instillation, decreased the severity of fibrosis, apoptosis, protected
alveolar structures, and increased the angiogenesis (Figure 4) [34].
Figure 4. Embryonic stem cells and iPSCs derived to alveolar type II cells, isolated alveolar type II
cells and lung spheroids (ATII cells, ATI cells and club cells) delivered intravenously or intratracheally
home to the sites of injury in the lungs where they exert anti-inflammatory and anti-fibrotic effects,
engage in paracrine signaling and immunomodulation, differentiate into local cell types, and activate
resident stem cells enhancing lung regeneration.
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4. Clinical Experiences
In recent years, at least three phase 1b non-randomized non-placebo clinical trials involving
stem cells and a clinical study using the lung stem/progenitor ATII cells have been published [35–38].
The main objective of these studies was to evaluate the safety and tolerability of the administered cells.
In addition, all of them also evaluated the potential beneficial effect that each one could have. In the
first clinical trial, 0.5 × 106 cells/kg of body weight of autologous MSCs isolated from adipose tissue
was endotracheally administered into 14 patients diagnosed with mild to moderate IPF; these patients
were followed up 12 months after the administration of cells [35]. In a second study, heterologous
MSCs isolated from placenta were administered intravenously into eight patients with moderate to
severe disease [36]. In this clinical trial, two doses of cells were administered and evaluated (1 × 106
and 2 × 106 cells/kg of body weight) and the patients were monitored for six months [36]. In the
third study, heterologous MSCs isolated from BM were administered intravenously into nine patients
with mild to moderate disease [38]. In this last study, the authors also administered and evaluated
three different cellular doses (20, 100, or 200 × 106 BM-MSCs); the patients were assessed until week
60 and 28 days after the administration of cells [38]. In all of these trials, during the treatment and
follow-up period, no serious or clinically significant side effects were observed [35,36,38]. Only the
third study reported two non-treatment-related deaths due to IPF progression (disease worsening
and/or exacerbation) [38]. Likewise, no studies reported changes in the functional tests of patients
or alterations in the quality of life indicators since the beginning of the treatment. The conclusions of
these trials were that either endobronchial or intravenous administration of stem cells is safe and well
tolerated [35,36,38].
In the other clinical study, ATII cells isolated from lungs of organ donors were administered
endotracheally, at a dose of 1000 to 1200 × 106 cells/patient, into 16 patients diagnosed with mild to
moderate and progressive disease [37]. In this study, to avoid ATII cell rejection reactions, patients
followed immunosuppressive and prophylaxis treatment and the rate of sensitization due to ATII cell
administration was similar to that observed in a blood transfusion [37]. No relevant side effects were
observed, and 13 of the 16 patients showed stabilization in the functional tests performed throughout
the one-year follow-up. Unlike the other three studies, patients walked further in the 6-min walk test
and also showed a decrease in the degree of dyspnoea and cough [37]. The conclusions of this study
were that ATII cell therapy is safe, well tolerated and with possible beneficial effects.
The limitations of these studies include their small sample size, lack of randomization, and lack
of a placebo arm. However, without doubt the encouraging results of these four studies will open the
doors to new treatments for IPF.
5. Conclusions and Future Perspectives
Preclinical and clinical data support the safety of stem cells and lung stem/progenitor cells as
a potential therapy for IPF. The precise mechanisms by which stem cells and lung progenitor cells
exert their positive effect are still not clear. These mechanisms involve multiple biological pathways,
including engraftment in damaged zones, differentiation into lung epithelial cells, immunomodulatory
ability, the secretion of anti-inflammatory and anti-fibrotic mediators, and the promotion of lung
endogenous repair. Regarding MSC lung therapies, it is important to note that most studies that
have used them have shown that the reparative/healing effects are mostly through the paracrine or
immunomodulatory effects on recipient lung tissue, but not by engraftment. Therefore, it would be
important to consider MSC therapy as a cell-based immunomodulatory therapy rather than considering
it only as a regenerative or reconstituting therapy. On the other hand, the use of allogeneic lung
stem/progenitor cells has shown to be a great potential cell therapy option for IPF patients. Moreover,
the use of ESCs and iPSCs derived into lung stem/progenitor cells for the repair of the lung after
injury and disease condition opens another door towards the development of regenerative therapeutics
for lung disease. However, the pluripotent nature of ESCs or iPSCs could present a potential risk of
teratogenic effects, which needs to be rigorously addressed before moving into human clinical trials.
Med. Sci. 2018, 6, 64 13 of 18
Regenerative stem cell therapy has generated a lot of hope amongst scientists and physicians who
seek more effective treatment strategies; nevertheless, because different approaches have been applied
in preclinical and clinical studies, many key questions remain unanswered. For instance, questions
about the effectiveness and efficiency of the route of administration (intravenous or endotracheal)
have not yet been resolved. Neither the doses nor the administration timetable nor the stage of the
disease at which it is better to start the cell treatment are well defined. Another important question
refers to the efficacy on the cell type that should be used, that is, BM-HSCs, BM-MSCs, adipose-MSCs,
placenta-MSCs, iPSCs, or lung stem/progenitor cells. Should autologous or heterologous cells be
used? Do they really engraft? To answer these important questions, a standardization of protocols
should be taken into account. In the majority of preclinical studies, cells have been administered in the
early inflammatory phase rather than in the late fibrotic phase. Consequently, the results of most of
these studies were positive. By contrast, the effectiveness of stem cell therapies progressively decays as
the cells are administered later, when the pro-fibrotic phase or fibrotic phase has already begun. Thus,
it could be possible that the positive effects of stem cell therapies are limited only to the inflammatory
phase and do not have any effect when fibrosis is already developed. However, with the use of stem
cells (that are more differentiated into lung progenitor cells) as ATII cells or even with the use of mature
ATII cells, the effectiveness increases even when the cells have been administered during the fibrotic
phase. Therefore, both the administration schedule and the cell type should be considered the most
important variables for the treatment of IPF.
Although IPF is not recognized as a genetic disease, in recent years, different genome-wide linkage
studies have identified genetic polymorphisms that could be associated with higher susceptibility
to the development of IPF [83]. Among all mucin 5 (MUC5), telomerase and surfactant protein
polymorphisms have been considered the highest genetic risk factor for IPF [83]. Therefore, combining
cell-based therapy and gene therapy may offer a new strategy for IPF intervention in the future. In this
sense, two different strategies will be important for the development of cell therapy. On the one hand,
for autologous cell therapies, it will be important to evaluate the IPF patients’ genome in order to know
whether the patients have polymorphisms related to the increased risk of fibrosis. On the other hand,
for heterologous cell therapies, it will be important to evaluate the cell donor genome. Finally, another
important issue to take into account will be the cell genetic modification, which allows for considerable
enhancement of the therapeutic activity. Some preclinical studies have already demonstrated that
cells that overexpress or downregulate genes involved in the development of fibrosis could also have
positive results restoring damage in pulmonary fibrosis [10,11,15,19].
The use of cell-based therapies to treat IPF is still at the experimental stage and many challenges
remain to be explored. Further investigations are necessary to establish the best strategy for using
cell-based therapies for the treatment of IPF. Overall, stem cell or lung progenitor cell therapy appears
to be a promising strategy to reduce or even reverse pulmonary fibrosis.
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